A small insomnia study associated benzodiazepine exposure density with cognitive impairment while finding a different pattern for Z-drugs.
What the source reports
The investigators assessed 120 patients using global cognition and several domain-specific tests. Benzodiazepine exposure density was associated with cognitive impairment in their adjusted analysis. The authors did not find the same association for Z-drug exposure and discussed differences in test performance across medications.
Limits of the evidence
The single-center sample was limited. Insomnia can precede recognition of dementia, so a prescription may follow an early disease symptom rather than cause the disease. The authors explicitly acknowledged that reverse causation was not fully excluded.
Implications for forensic review
A cognitive-injury opinion needs the chronology of symptoms, baseline testing, medication changes, sleep disturbance, and alternative neurological explanations. The study does not establish that a benzodiazepine caused dementia or that Z-drugs are free of cognitive or other safety risks.
Source and related reading
Source reviewed: Association Between Z Drugs Use and Risk of Cognitive Impairment in Middle Aged and Older Patients W (PMC8696350). This article summarizes the supplied paper; forensic applications above are interpretive analysis.
Related reading: Persistent Insomnia Complaints After Hypnotics May Require Measuring Sleep, Not Assuming No Sleep Occurred; Oral and Intravenous Midazolam Probes Answered Different Questions in a Napabucasin Study.
Leave a Reply